Richard Furman, M.D., director of Weill's CLL Research Center, participates in a panel discussion about therapy for patients with chronic lymphocytic leukemia (CLL) whose tumors harbor a 17p deletion. Read more
Pathologist Christopher Mason and his research team gathered DNA from turnstiles, ticket kiosks, railings and benches in a transit system shared by 5.5 million riders every day. Read more
Manish A Shah, M.D., director of gastrointestinal oncology, discusses a recent phase II study of FOLFOX with or without onartuzumab, a MET inhibitor, for the treatment of metastatic gastroesophageal adenocarcinoma. Read more
Mark Rubin, director of Weill Cornell's Institute for Precision Medicine, recently traveled to the White House as President Barack Obama unveiled a new $215m precision medicine initiative. Read more
Image-guided radiotherapy (IGRT) delivers highly accurate doses of radiation therapy to targeted areas in the brain while maximizing patient comfort in a procedure called stereotactic radiosurgery. Read more
John Leonard, M.D., associate director of clinical trials at the cancer center and director of Weill Cornell's Lymphoma Program, highlights advances in lymphoma research and clinical care. Read more
Irene Price is an early beneficiary of “precision medicine,” an approach that replaces the traditional one-size-fits-all cancer treatment paradigm with one that focuses on targeted, individualized care using a patient’s own genetic profile and medical history. Read more
Manish Shah, M.D., director of gastrointestinal oncology, talks about a recent phase II study of mFOLFOX paired with the MET inhibitor onartuzumab for the treatment of metastatic, HER2-negative gastroesophageal adenocarcinoma. Read more
Richard Furman, director of Weill’s Chronic Lymphocytic Leukemia Research Center, weighs in on debates about when and how to treat patients with CLL. Read more
Cancer: It’s personal, and not only on an emotional level, but a molecular one. Every patient's cancer is unique, driven by distinct biological factors. So, too, should every patient’s treatment. Read more
Himisha Beltran and Christopher Barbieri were awarded Challenge Awards from the Prostate Cancer Foundation, two of only six distributed nationwide. Read more
Gail Roboz, director of the Leukemia Program, presented an educational platform discussing the introduction of epigenetic and personalized therapies targeting AML at the ASH Annual Meeting. Read more
Jia Ruan, M.D., Ph.D., talks to OncLive about the results of a phase II study that show sustained remissions experienced by patients treated with the combination of lenalidomide and rituximab as initial treatment for mantle cell lymphoma (MCL). Read more
Researchers have discovered more information about an elusive part of our cells, which could lead to a better understanding of how prostate cancer develops. Read more